VANI earnings analysis
What we found in VANI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing depicts Vivani as an early-stage clinical company with no approved products, continuing losses, and a substantial need for additional capital. The six-month net loss improved modestly to $13.2 million from $13.4 million year over year, and the company plans mid-2026 Phase 1 trials for NPM-139 and NPM-133. However, regulatory uncertainty around the 505(b)(2) pathway, potential clinical-study requirements, litigation exposure, and emerging tariff risks remain significant headwinds.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Six-Month Loss Improved Slightly
- Six-month net loss was $13.2 million, compared with $13.4 million in the six months ended June 30, 2025, an improvement of $0.2 million, or approximately 1.5%.
- Clinical Pipeline Advancing
- Management plans to initiate Phase 1 clinical trials for NPM-139 and NPM-133 in mid-2026, while NPM-115 has completed a Phase 1 study.
- Regulatory Experience Remains Early
- The company has been granted 1 U.S. IND and 1 Australian HREC request, although it has submitted 0 NDAs to the FDA or comparable foreign agencies.
- Disclosure Controls Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no material changes in internal control over financial reporting during or after the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Funding Requirement
- The company reported a six-month net loss of $13.2 million and an accumulated deficit of $161.7 million as of June 30, 2026. Management states that substantial additional financing will be required and that failure to obtain capital could delay, reduce, or terminate development activities.
- 505(b)(2) Pathway Uncertainty
- If the FDA does not accept the Section 505(b)(2) pathway for NPM-139 or NPM-133, additional clinical studies, including a cardiovascular outcomes study, may be required. The filing states this could create significant additional costs and delays.
- Tariff and Supply-Chain Exposure
- The filing identifies new trade-policy exposure, including a U.S. baseline tariff of 10% and a potential 15% tariff on most imports from the European Union. Tariffs on APIs, raw materials, and device components could increase costs and disrupt research, development, and production timelines.
- Material Litigation Exposure
- The company faces a pending Oppenheimer breach-of-contract claim seeking no less than $1.625 million, while Pixium claims approximately €5.1 million, or about $5.6 million, in damages in separate litigation.
What they said about what is next.
No quantitative revenue or EPS guidance is provided in the extracted 10-Q text. The filing states that the company does not anticipate product-sale revenue for the foreseeable future and may never become profitable.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Vivani Medical's Q4 2026 results reflect ongoing challenges, with reported revenue of $0.0 and an EPS of -$0.09, consistent with prior periods, indicating continued operational losses. R&D expenses slightly increased to…
- 10-K · March 26, 2026
- Vivani Medical is a clinical‑stage biopharma developing NanoPortal™ subdermal implants (lead program NPM-139 semaglutide) and recently reported positive first‑in‑human LIBERATE-1 data and preclinical semaglutide…
- 10-Q · November 13, 2025
- Vivani reported a Q3 net loss per share of $(0.11), unchanged from the prior-year quarter, while total operating expenses rose to $6,725k from $6,309k (up $416k). Cash and cash equivalents declined sharply to $2,628k at…
- 10-Q · May 13, 2025
- Vivani reported a Q1 2025 net loss of $6,302,000 (EPS -$0.11) versus a net loss of $6,039,000 (EPS -$0.12) in Q1 2024. The Company achieved clinical milestones (first GLP‑1 implant administered and full enrollment in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VANI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever